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Abstract	
Background:	Antibody	titres	and	vaccine	effectiveness	decline	within	six	months	after	influenza	
vaccination	in	older	adults.	Biannual	vaccination	may	be	necessary	to	provide	year-round	protection	
in	the	tropics	where	influenza	is	present	throughout	the	year.	
Methods:	Tropical	Influenza	Control	Strategies	(TROPICS1)	was	a	single-centre,	1:1	randomised,	
observer-blinded,	active-comparator	controlled,	superiority	study	in	200	community-resident	adults	
aged	≥65	years.	Participants	received	standard-dose	trivalent	inactivated	influenza	vaccination	(IIV3)	
at	enrolment,	and	either	tetanus-diphtheria-pertussis	vaccination	or	IIV3	six	months	later.	Primary	
outcome	was	the	proportion	of	participants	with	haemagglutination-inhibition	(HI)	geometric	mean	
titre	(GMT)	≥1:40	one	month	after	the	second	vaccination	(Month	7).	Secondary	outcomes	included	
GMTs	to	Month	12,	the	incidence	of	influenza-like	illness	(ILI),	and	adverse	reactions	after	
vaccination.		This	study	is	registered	with	ClinicalTrials.gov:	NCT02655874.	
Findings:	At	Month	7,	the	proportion	of	participants	with	a	HI	tire	≥1:40	against	A/H1N1	increased	
by	21·4%	(95%	CI	8·6-33·4)	in	the	six-monthly	vaccination	group.	This	proportion	was	not	
significantly	higher	for	A/H3N2	(4·3,	95%	CI	-1·1-10·8)	or	B	(2·1,	95%	CI	-2·0-7·3).	Six-monthly	
vaccination	significantly	increased	GMTs	against	A/H1N1	and	A/H3N2	at	Month	7,	but	not	B.	
Participants	receiving	repeat	IIV3	reported	a	significantly	lower	incidence	of	ILI	in	the	six	months	
after	the	second	vaccination	(relative	vaccine	efficacy	of	57·1%,	95%	CI	0·6-81·5).	The	frequency	of	
adverse	events	was	similar	after	first	or	second	influenza	vaccination.		
Interpretation:	Six-monthly	influenza	vaccination	in	older	residents	of	tropical	countries	is	a	simple	
intervention	with	the	potential	for	improving	protection	against	infection.		
Funding:	National	Healthcare	Group	
	
	
Research	in	context		
Evidence	before	this	study		
The	TROPICS1	study	was	developed	following	the	findings	of	a	systematic	review	of	
haemagglutination-inhibition	(HI)	antibody	persistence	after	standard-dose	inactivated	influenza	
vaccination	in	older	adults.	The	influenza	virus	circulates	year-round	in	tropical	regions,	and	year-
round	persistence	of	antibodies	against	infection	is	expected	to	be	advantageous.	MEDLINE,	
EMBASE,	Global	Health	and	other	relevant	databases	and	the	reference	lists	of	all	included	studies	
were	searched	for	studies	which	measured	strain	specific	HI	titres	up	to	360	days	after	influenza	
vaccination.	Databases	were	searched	with	the	keywords	(“influenza”	or	“flu”),	(“immune”	or	
“vaccine”),	(“haemagglutination	or	hemagglutination”	and	“inhibition”	or	“assay”),	(“HI”	or	“HAI”	or	
“HIA”)	in	September	2015.	This	search	yielded	2864	articles,	which	were	screened	to	identify	studies	
meeting	the	selection	criteria.	16	articles	met	these	criteria	and	were	reviewed.	The	overall	
conclusion	from	this	review	was	that	HI	antibody	responses	following	single	dose	influenza	
vaccination	do	not	reliably	persist	year-round	in	older	adults.	Titres	fell	significantly	from	the	first	six	
months	after	vaccination,	to	the	second	six	months.	By	one	year	after	vaccination,	HI	titres	were	
similar	to	pre-vaccination.	No	studies	of	the	serological	or	clinical	outcomes	following	six-monthly	
vaccination	were	uncovered.		
Added	value	of	this	study		
This	trial	was	designed	to	compare	the	serological	outcomes	following	annual	versus	six-monthly	
standard-dose	influenza	vaccination	in	older	adults	in	a	randomised	manner.	Study	participants	were	
otherwise	healthy,	community-resident	adults	aged	65	years	or	older.	The	study	was	conducted	in	
Singapore,	a	tropical	country	which	typically	experiences	year-round	influenza	virus	activity	and	
biannual	epidemics	coinciding	with	Northern	and	Southern	hemisphere	winters.	The	proportion	of	
subjects	with	a	HI	titre	≥1:40,	which	traditionally	is	used	to	indicate	seroprotection,	increased	by	
21%	against	A/H1N1.	This	proportion	was	not	significantly	higher	for	H3N2	or	B.	HI	titres	against	
Influenza	A/	H1N1	and	A/H3N2	were	significantly	higher	following	repeat	vaccination,	though	no	
different	for	B.	The	group	receiving	repeat	influenza	vaccination	also	experienced	57%	less	
symptomatic	respiratory	illness	and	less	utilization	of	health	services.	Adverse	events	following	
repeat	vaccination	were	numerically	lower	than	after	the	first	vaccine.	
Implications	of	all	the	available	evidence		
Our	results	indicate	that	in	older	adult	residents	in	the	tropics,	biannual	vaccination	is	able	to	offer	
better	year-round	protection	compared	with	single-dose	vaccination.	They	also	suggest	that	the	
immune	responses	to	repeat	influenza	vaccination	are	reduced	in	older	adults,	which	may	be	due	to	
interference	from	pre-vaccination	immunity.	Studies	performed	over	multiple	seasons,	and	which	
include	changes	in	vaccine	strains	are	needed.	If	serological	advantages	are	confirmed,	large	studies	
to	determine	if	this	translates	to	reduced	influenza	infection	would	be	needed.		
	
	
	
	
	
	
	
	
	
	
	
Background	
The	inactivated	seasonal	influenza	vaccine	in	current	use	contains	purified	surface	antigens	from	two	
influenza	virus	types:	influenza	A	and	B.	Antigens	with	two	components	of	influenza	A	virus	subtypes	
(H1N1	and	H3N2),	and	either	one	or	two	components	of	influenza	B	viruses	(B/Victoria	and/or	
B/Yamagata-lineages)	are	included	in	trivalent	and	quadrivalent	vaccines	respectively.		Inactivated	
vaccine-induced	protection	against	influenza	infection	is	primarily	conferred	via	antibody	to	the	
haemagglutinin	(HA)	surface	antigen.1		
Both	the	HA	and	NA	proteins	for	influenza	A	and	B	undergo	frequent	change	through	antigenic	drift,	
and	new	antigenic	strains	emerge.	Influenza	virus	surveillance	data	reported	to	the	World	Health	
Organisation	(WHO)	global	network	of	national	influenza	centres	(GISRS;	Global	Influenza	
Surveillance	and	Response)	is	reviewed	by	the	WHO,	and	every	six	months	recommendations	for	the	
composition	of	strains	in	the	upcoming	seasonal	vaccine	are	updated.2	These	recommendations	are	
published	in	September	for	the	next	Southern	hemisphere	winter,	and	in	February	for	the	next	
Northern	hemisphere	winter.	Between	hemisphere	winters,	a	change	in	the	strain	composition	of	
the	trivalent	vaccine	has	been	recommended	approximately	half	the	time.	
A	close	match	between	the	viral	antigens	(HA	and	NA)	in	the	vaccine	and	the	circulating	strain	is	
important	to	maximise	protection	against	infection.3	Vaccine	effectiveness	(VE)	also	depends	on	an	
adequate	immune	response	to	the	vaccine.	Immune	responses	to	the	influenza	vaccine	are	reduced	
in	older	adults	due	to	an	age-related	decline	in	the	immune	system,	termed	immunosenescence.	
This	results	in	lower	antibody	titres	immediately	after	vaccination,	and	a	significant	fall	in	antibody	
titres	in	older	adults	within	six	months.4	
A	consequence	of	these	limitations	is	the	failure	of	vaccination	to	maintain	clinical	protection	over	
the	course	of	a	typical,	temperate-climate	winter	season	of	four	to	six	months.	Observational	studies	
have	consistently	reported	lower	VE	in	the	second	quarter	after	vaccination	compared	with	the	first	
quarter	for	all	age	groups.5	To	improve	vaccine	effectiveness	in	older	adults,	a	number	of	alternative	
vaccines	have	been	developed.	This	includes	the	Sanofi	Fluzone®	High-Dose	vaccine,	with	four-times	
the	regular	amount	of	HA;	adjuvanted	vaccines	such	as	the	Seqirus	FluAd®,	which	includes	MF-59	to	
form	an	oil	in	water	emulsion;	and	the	recombinant	influenza	vaccine	Flublok®,	which	contains	three	
times	the	regular	amount	of	HA.6–8	While	these	have	been	shown	to	reduce	virologically	confirmed	
infections	in	older	adults,	the	benefit	over	standard-dose	vaccine	is	small,	with	a	relative	reduction	in	
infection	rates	of	only	24-30%.	In	addition,	long-term	antibody	data	is	lacking,	and	it	is	not	known	if	
these	newer	vaccines	will	extend	protection.	
The	duration	of	vaccine-induced	protection	is	a	critical	issue	in	the	sub-tropics	and	tropics,	where	
influenza	transmission	often	occurs	year-round,	with	biannual	peaks.9	Twice-annual	vaccination	
coinciding	with	those	peaks	might	be	beneficial,	where	each	vaccination	can	be	synchronised	with	
both	the	waning	of	antibody	titres	and	biannual	WHO	vaccine	strain	recommendations.	Current	
vaccine	recommendations	remain	for	annual	administration,	however,	as	there	is	little	clinical	or	
public	health	evidence	available	to	determine	whether	one	or	two	doses	per	year	is	the	best	
strategy.	
Repeat	vaccination	within	three	months	following	the	first	injection	has	been	previously	investigated	
with	mixed	results.	Studies	in	residents	of	long-term	care	facilities	and	individuals	with	end-stage	
renal	failure	found	no	clinically	significant	improvement	in	haemagglutination-inhibition	(HI)	
antibody	titres	with	repeat	vaccination,	whereas	a	recent	study	in	recipients	of	a	solid	organ	
transplant	observed	significantly	higher	antibody	titres	when	an	influenza	vaccine	was	re-
administered	after	five	weeks.10–12	These	studies,	however,	were	conducted	with	the	aim	of	
improving	protection	for	the	duration	of	a	temperate	winter	season,	rather	than	year-round	
protection.		
An	observational	study	of	antibody	persistence	conducted	over	2016-17	among	older	adults	in	Hong	
Kong	proposed	that	six-monthly	vaccination	improved	protection	against	circulating	seasonal	
influenza	strains.13	Similar	to	observations	following	repeated	annual	vaccination,	the	results	also	
raised	the	concern	that	more	frequent	vaccination	may	actually	impair	immune	responses.14		
Singapore	is	a	tropical	city-state,	where	influenza	epidemics	typically	occur	biannually,	coinciding	
with	the	Northern	and	Southern	hemisphere	winters,	and	endemic	virus	activity	persists	year-round.	
The	TROPICS1	study	is	a	clinical	trial	of	six-monthly	versus	annual	influenza	vaccination	in	older	
adults,	with	the	aim	of	determining	if	a	repeat	influenza	vaccine	at	six	months	is	able	to	improve	the	
year-round	immune	markers	of	protection	against	influenza.		
	
	
	
	
	
	
	
	
	
	
	
	
	
Methods	
Study	design	and	setting	
Tropical	Influenza	Control	Strategies	(TROPICS1)	was	a	single-centre,	1:1	randomised,	observer-
blinded,	active-comparator	controlled,	parallel-group	superiority	study	of	a	repeat	influenza	vaccine	
administered	six-months	after	initial	vaccination.	Study	procedures	were	conducted	at	Tan	Tock	
Seng	Hospital	in	Singapore.		
The	study	protocol	was	approved	by	the	Institutional	Review	Board	with	oversight	of	Tan	Tock	Seng	
Hospital,	the	Domain	Specific	Review	Board	(DSRB	2015/01047).	The	study	was	conducted	without	
significant	amendment	to	the	published	protocol.15	
Participants	
Study	participants	were	adults	aged	65	years	or	over,	living	independently	in	the	community	who	
were	able	to	comply	with	the	study	protocol.	All	participants	provided	written	informed	consent.	
Participants	were	mainly	enrolled	from	senior	activity	centres	and	community	centres,	with	no	
restrictions	based	on	gender	or	race.	For	inclusion	in	the	study,	all	participants	must	not	have	
received	any	influenza	vaccine	in	the	preceding	ten	months	nor	have	been	diagnosed	with	a	
virologically	confirmed	influenza	infection.	
Major	exclusion	criteria	included	known	systemic	hypersensitivity	to	any	of	the	vaccine	components,	
or	prior	life-threatening	reaction	to	influenza	vaccination	including	a	history	of	Guillain-Barré	
syndrome	(GBS)	within	six	weeks	following	previous	vaccination.	Other	exclusion	criteria	included	a	
known	or	suspected	congenital	or	acquired	immunodeficiency,	or	receipt	of	immunosuppressive	
therapy	within	the	previous	six	months,	such	as	anti-cancer	chemotherapy,	radiation	therapy,	or	
long-term	systemic	corticosteroid	therapy.	Participation	in	the	study	was	delayed	if	the	individual	
had	an	acute	respiratory	illness,	fever	≥37·5°C,	or	moderate	or	severe	acute	illness/infection	on	the	
day	of	enrolment.		
Intervention	
Following	enrolment,	all	participants	received	an	injection	of	a	standard-dose,	inactivated	trivalent	
influenza	(IIV3)	vaccine	(Fluzone®,	Sanofi-Pasteur,	PA,	USA).	Six	months	after	enrolment,	participants	
allocated	to	the	control	group	received	an	injection	of	Tetanus-diphtheria-pertussis	(TDaP)	vaccine	
(Boostrix®,	GSK,	Brentford,	UK),	while	participants	allocated	to	the	experimental	group	received	a	
repeat	IIV3	injection	(Influvac®,	Abbott	Laboratories,	IL,	USA).	The	vaccines	were	provided	in	ready-
to-use	0·5-ml	syringes	and	administered	intramuscularly,	in	the	deltoid	muscle.		
Influenza	vaccine	manufacturer	changed	between	first	and	second	influenza	vaccination	due	to	a	
countrywide	replacement	by	Sanofi	of	the	trivalent	Fluzone®	with	a	quadrivalent	formulation.	To	
ensure	the	intervention	group	received	a	trivalent	formulation,	Influvac®,	Abbott	Laboratories,	IL,	
USA	was	used	for	the	second	dose.		Strains	included	in	both	vaccines	did	not	change,	reflecting	the	
contemporaneous	World	Health	Organisation	recommendations	for	the	Southern	hemisphere	
winter	2016	and	Northern	hemisphere	winter	2016/7,	and	comprised:	A/California/7/2009	
(H1N1)pdm09-like	virus,	A/Hong	Kong/4801/2014	(H3N2)-like	virus,	and	B/Brisbane/60/2008-like	
virus.2	
Procedures	
Venous	blood	samples	were	obtained	from	participants	for	immunogenicity	assessment	at	
enrolment	(Month	0,	pre-injection),	Month	1	(21-28	days	after	enrolment),	Month	6	(166-194	days	
after	enrolment),	Month	7	(21-28	days	after	second	vaccine),	and	Month	12	(346-376	days	after	
enrolment).	
Participants	were	monitored	for	30	min	after	vaccination	for	immediate	adverse	events	and	
reactogenicity.	Diary	cards	were	distributed	on	the	day	of	vaccination	to	record	solicited	local	(pain,	
redness,	and	induration)	and	systemic	(fever,	headache,	fatigue,	arthralgia,	chills,	malaise,	myalgia,	
and	vomiting)	reactions	for	seven	days	after	vaccination.		
All	other	adverse	events	(AEs)	were	recorded	for	seven	days	after	each	vaccination,	while	adverse	
events	considered	to	be	serious	(SAEs)	were	recorded	for	28	days.	The	relation	of	AEs	and	SAEs	to	
study	vaccines	was	determined	by	study	investigators	according	to	ICH	guidelines	and	protocol-
specified	safety	considerations.	
Participants	were	contacted	every	two	weeks	till	final	visit	at	Month	12	by	either	text	message,	
phone	call	or	clinic	visit	as	surveillance	for	clinical	endpoints.	At	each	contact,	participants	were	
asked	about	any	symptoms	of	an	influenza-like	Illness	(ILI),	using	the	European	Centre	for	Disease	
Prevention	and	Control	(ECDC)	clinical	case-definition:	the	sudden	onset	of	systemic	symptoms	
(fever	or	feverishness,	malaise,	headache	or	myalgia)	and	respiratory	symptoms	(cough,	coryza,	
shortness	of	breath	or	sore	throat).16	Subjects	with	the	sudden	onset	of	respiratory	symptoms,	with	
or	without	accompanying	systemic	symptoms,	were	recorded	as	having	an	acute	respiratory	illness	
(ARI).	Laboratory	confirmation	of	influenza	infection	was	not	pursued.	
In	addition	to	symptoms,	participants	were	also	asked	regarding	unscheduled	doctor	(e.g.	general	
practitioner,	polyclinic)	and	hospital	visits	(e.g.	emergency	department,	hospitalisation)	since	the	
previous	contact.		
Outcomes	
The	pre-specified	primary	outcome	for	this	study	was	the	percentage	of	participants	with	a	
haemagglutination-inhibition	(HI)	titre	≥1:40	for	each	of	the	influenza	strains	present	in	the	
administered	influenza	vaccine	at	Month	7,	one	month	after	the	second	vaccination.	Other	
serological	outcomes	include	a	comparison	by	intervention	group	of	geometric	mean	titres	(GMT)	
and	the	geometric	mean	fold-rise	(GMFR)	pre-	and	post-vaccination	from	Month	7	to	12.	
Seroconversion	was	also	measured	using	the	standard	definition	of	a	pre-vaccination	HI	titre	<10	
and	post-vaccination	HI	titre	≥40	or	at	least	a	4-fold	increase	in	HI	titres	from	a	pre-vaccination	HI	
titre	≥10.	
Clinical	outcomes	included	the	number	of	participants	reporting	an	influenza-like-illness,	and	the	
number	of	participants	reporting	healthcare	utilisation	(emergency	rooms	visits	and	hospitalisations	
in	each	group)	across	vaccine	groups	from	Month	6	to	12.		
Sample	size	
A	sample	size	of	200	(100	per	group)	was	estimated	to	offer	more	than	80%	power	to	detect	a	20%	
difference	in	the	proportion	of	participants	with	a	HI	titre	≥1:40	at	Month	7.	This	assumed	a	60%	
seroprotection	rate	in	the	control	group,	a	loss	to	follow	up	rate	of	15%,	and	a	two-sided	significance	
level	(α)	of	5%.	
Randomisation	and	blinding	
Participants	were	assigned	to	intervention	groups	through	a	computer-generated	randomisation	
sequence	created	using	the	‘blockrand’	package	on	the	R	statistical	software	program.17	The	
randomisation	sequence	was	generated	by	a	statistician	with	no	clinical	involvement	in	the	trial.	
Randomisation	was	stratified	by	participant	age	(≥65-74,	≥75	years)	and	used	random	block	sizes	of	
2,	4	and	6.	
Participant	group	allocation	was	performed	by	an	unblinded	vaccine	team	who	were	solely	
responsible	for	preparing	and	administering	the	vaccines	at	the	Month	6	study	visit.	This	team	also	
securely	stored	vaccination	documents	revealing	participant	group	assignment.	Blinded	study	
personnel	were	not	allowed	to	be	present	during	preparation	and	administration	of	the	vaccines.		
Contents	of	prepared	syringes	were	masked	with	an	opaque	tape,	and	participants	were	asked	to	
look	away	during	vaccine	administration	to	ensure	participant	blinding	to	group	allocation.	The	
unblinded	team	was	not	involved	in	collecting	safety	data	or	performing	any	other	study	procedures.		
Participants,	investigators,	study	staff	members	and	laboratory	personnel	were	all	blinded	to	group	
assignment	until	after	serological	studies	for	the	study	primary	endpoint	were	completed.	
Laboratory	methods	
Blood	samples	were	processed	immediately	after	collection,	and	serum	stored	at	-80°C,	before	being	
shipped	frozen	to	the	WHO	Collaborating	Centre	for	Reference	and	Research	on	Influenza	in	
Melbourne,	Australia	for	the	haemagglutination-inhibition	(HI)	assay.			
HI	assays	were	performed	on	serum	samples	following	standardized	protocols	using	the	egg-derived	
vaccine	viruses	strains	and	turkey	red	blood	cells.18	HI	titres	were	expressed	as	the	reciprocal	of	the	
highest	dilution	of	serum	where	hemagglutination	was	prevented	(from	1:10	to	a	maximum	of	
1:20,480)	and	analysed	on	a	log2	scale	(titres	<10	and	≥20,480	were	assigned	a	value	of	5	and	20,480	
respectively).		
Statistical	methods	
Continuous	variables	were	compared	between	groups	with	unpaired	t	tests,	and	the	paired	t	test	
was	used	to	compare	GMTs	within	study	groups	at	baseline	and	after	vaccination.	For	categorical	
variables,	we	assessed	differences	between	vaccine	groups	with	Fisher's	exact	tests.	Linear	
regression	was	used	to	identify	predictors	of	HI	response	to	vaccination,	and	regression	lines	
compared	by	analysis	of	covaraince.			
As	per	the	study	protocol,	analysis	for	serological	and	clinical	endpoints	were	performed	in	the	
intention-to-treat	population,	while	safety	data	was	analysed	based	on	the	actual	vaccine	received.	
All	analyses	were	performed	using	the	R	statistical	software,	version	3·4·1.17	
This	study	is	registered	with	ClinicalTrials.gov,	identifier	NCT02655874.	
Role	of	the	funding	source	
TROPICS1	was	an	investigator-initiated	study,	funded	by	the	National	Healthcare	Group.	The	study	
sponsor	was	not	involved	in	study	design;	in	the	collection,	analysis,	and	interpretation	of	data;	in	
the	writing	of	the	report;	or	in	the	decision	to	submit	the	paper	for	publication.	
	
Results	
200	participants	were	enrolled,	with	100	randomly	assigned	to	repeat	IIV3	vaccination	at	six	months,	
and	100	assigned	to	the	control	group.	All	200	participants	received	influenza	vaccination	at	study	
enrolment	(Figure	1).	192	(96%)	received	a	repeat	vaccine	after	six-months	and	were	included	in	the	
intention-to-treat	(ITT)	and	safety	analysis.	189	(95%)	participants	received	the	allocated	vaccine	and	
were	included	in	the	per-protocol	(PP)	analysis.		
Participants	were	enrolled	and	received	the	first	study	vaccine	from	May	to	November	2016.	The	
final	study	visit	was	in	October	2017.	The	epidemiological	week	of	vaccination	visits	and	the	weekly	
incidence	of	PCR-confirmed	influenza	infections	in	Singapore	from	WHO	surveillance	data	is	shown	
in	Figure	2.	
Baseline	characteristics	of	the	participants	in	each	group	were	similar	(Table	1).		
Immunogenicity	
HI	antibody	responses	to	the	first	influenza	vaccine	administered	met	traditional	licensing	criteria	for	
older	adults	set	by	the	Center	for	Biologics	Evaluation	and	Research	(CBER)	for	all	three	strains	at	
Month	1	(Figure	3).19		
Antibody	titres	declined	significantly	from	Month	1	to	6	for	all	three	influenza	strains	(all	p<0.0001,	
paired	t-test).	However,	only	for	A/H1N1	did	the	proportion	of	subjects	with	a	HI	titre	≥1:40	decline	
significantly	(from	83.1%	to	58.5%),	with	this	proportion	>95%	at	Month	6	for	both	A/H3N2	and	B.	
Following	repeat	vaccination,	there	was	a	statistically	significant	increase	in	the	proportion	of	
participants	with	a	HI	titre	≥1:40	at	Month	7	for	A/H1N1,	with	an	absolute	increase	of	21.4%	(95%	CI	
8·6-33·4,	p=0·0011).	A	non-statistically	significant	increase	in	this	proportion	was	observed	for	
A/H3N2	(4·3%,	95%	CI	-1·1	to	10·8,	p=0·088)	and	B	(2·1%,	95%	CI	-2	to	7·3,	p=0·152).		
Repeat	IIV3	vaccination	significantly	improved	the	HI	Geometric	Mean	Titre	(GMT)	against	the	
influenza	vaccine	subtypes	A/H1N1	(63·9,	95%	CI	52·7-77·4	vs	35·7,	95%	CI:	28·8-44·4,	p<0·0001)	and	
A/H3N2	(238·7,	95%	CI	195·3-291·8	vs.	174·0,	95%	CI	141·1-214·6,	p=0·030)	at	Month	7.	This	
significantly	higher	GMT	following	repeat	vaccination	did	not	persist	to	Month	12	for	either	influenza	
A	subtype,	while	no	significant	difference	in	GMT	was	observed	for	influenza	B	at	either	time	point.	
From	Month	6	to	12,	GMTs	declined	significantly	for	A/H1N1	and	A/H3N2	in	participants	receiving	
annual	vaccination	(p<0·0001	and	0·0002	respectively).	In	the	six-monthly	vaccine	group	antibody	
titres	were	not	significantly	different	between	these	two	timepoints.	The	immune	responses	to	
influenza	B	again	formed	an	outlier,	with	no	significant	change	in	GMT	for	either	group	from	Month	
6	to	12.	See	appendix	for	full	GMTs	prior	to	Month	7	(pp1-3).	
Using	the	GMT	at	enrolment	(Month	0)	as	baseline,	the	geometric	mean	fold	rise	(GMFR)	was	
significantly	higher	in	the	six-monthly	vaccination	group	at	Month	7	and	12	for	A/H1N1	and	at	
Month	7	for	A/H3N2,	but	not	significantly	different	for	B	(Figure	4).	Similarly,	a	significant	increase	in	
GMFR	was	evident	at	Month	7,	compared	with	Month	6	in	the	six-monthly	vaccination	group.		
GMTs	were	significantly	lower	in	the	six-monthly	vaccination	group	following	the	second	vaccination	
compared	with	first	(Month	7	vs	Month	1,	p<0.01	for	all).	Linear	regression	of	the	change	in	log2	titre	
following	first	and	second	influenza	vaccination,	indicated	increases	in	HI	titre	were	smaller	
following	the	second	vaccination,	even	when	the	pre-vaccination	titre	was	zero	(Figure	5).	As	a	
result,	the	proportion	of	participants	with	a	four-fold	or	greater	increase	in	HI	titre	in	the	repeat	
vaccination	group	was	substantially	lower	compared	with	the	first	vaccination:	75·5%	vs.	21·6%	to	
A/H1N1,	76·0%	vs.	12·4%	to	A/H3N2	and	47·4%	vs	3·1%	to	B	(p<0·0001	for	all	three	influenza	
strains).	The	proportion	of	participants	meeting	the	protocol	definition	for	seroconversion	was	also	
significantly	lower	(see	appendix	p4).	
Linear	regression	of	the	baseline	characteristics,	including	age,	sex,	co-morbidity	index	or	previous	
vaccination	identified	no	significant	predictors	of	GMT	at	Month	1	or	7.	GMT	pre-vaccination	was	a	
significant	correlate	of	post-vaccination	titres	at	all	time	points	(p<0·0001	for	all	3	influenza	
types/subtypes	at	Month	1).		
Serological	results	were	not	significantly	different	when	analysed	by	ITT	or	PP	(see	appendix	pp1-3	
for	the	PP	analysis).	
Vaccine	Efficacy	
A	significant	reduction	in	the	proportion	of	participants	reporting	an	acute	respiratory	infection	(ARI)	
or	influenza-like	illness	(ILI)	was	observed	in	the	group	who	received	the	repeat	influenza	vaccine	
(Table	2).	From	Month	6	to	12,	seven	(7·2%)	of	participants	in	the	experimental	group	reported	an	
ILI,	and	16	(16·8%)	participants	in	the	control.	Vaccine	efficacy	against	ILI	was	57·1%	(0·6-81·5%,	
p=0·047).	Consistent	with	this	reduced	ILI	incidence,	a	reduction	in	emergency	department	
attendances	and	hospital	admission	was	observed	in	the	six-monthly	vaccination	group	with	an	
estimated	VE	of	34·7%.	Of	the	three	attendances	attributable	to	an	acute	respiratory	condition,	all	
were	in	the	control	group.	Diagnoses	were	of	an	upper	respiratory	tract	infection,	a	lower	
respiratory	tract	infection	and	an	infective	exacerbation	of	chronic	airways	disease.		
The	incidence	of	ARI,	ILI	and	healthcare	attendances	were	not	significantly	different	between	groups	
from	Month	0	to	6	(see	appendix	p4)	
Safety	
197	participants	returned	a	diary	card	after	the	first	vaccination,	and	32	(16·2%)	participants	
reported	57	solicited	adverse	events	(AE)	in	the	seven	days	after	vaccination.	Ten	(10·0%)	of	100	
participants	who	received	a	second	influenza	vaccine	reported	19	solicited	adverse	events	(see	
appendix	pp4-5	for	a	full	description	of	the	nature	and	duration	of	AEs).	This	lower	incidence	of	
adverse	events	was	not	significantly	different	(p=0·162).	The	majority	of	reported	adverse	events	
were	short-lived	and	of	only	mild	severity.	Seven	(3·6%)	AEs	were	reported	as	moderate	or	more	
severe	after	the	first	vaccination,	and	one	(0·5%)	of	participants	reported	an	AE	persisting	for	more	
than	seven	days.	Following	the	second	influenza	vaccination,	two	(2·0%)	of	AEs	were	reported	as	
moderate	or	more	severity,	while	none	persisted	for	more	than	seven	days.	
Some	28	(30·4%)	of	participants	receiving	the	TDaP	vaccine	reported	a	solicited	AE.	This	was	
significantly	more	common	than	either	the	first	(p=0·0078)	or	second	(p=0·0005)	influenza	
vaccination	and	probably	reflects	reactogenicity	from	the	alum	adjuvant.	Eight	(5·4%)	of	all	solicited	
AEs	were	reported	as	of	moderate	or	more	severity,	while	six	(6·5%)	persisted	for	more	than	seven	
days.	
Two	serious	adverse	events	were	recorded	in	the	month	after	the	second	vaccination,	one	in	each	
vaccination	group.	Neither	were	assessed	by	study	investigators	as	related	to	vaccination.		
	
	
	 	
Discussion	
TROPICS1	is	the	first	randomised	clinical	trial	of	six-monthly	versus	annual	influenza	vaccination.	Our	
results	show	that	a	repeat	standard-dose	influenza	vaccine	administered	after	six	months	in	older	
adults	can	significantly	increase	strain-specific	antibody	titres.	Repeat	vaccination	also	correlated	
with	a	significant	reduction	in	symptomatic	respiratory	illness	and	utilization	of	health	services.			
This	finding	has	important	implications	for	influenza	vaccination	strategies	in	tropical	and	sub-
tropical	climates	where	influenza	virus	activity	is	not	confined	to	a	short	winter	season.	With	aging	
demographics	and	developing	economies	resulting	in	an	increasing	demand	for	healthcare	across	
much	of	the	tropics	and	sub-tropics,	a	biannual	vaccination	schedule	could	have	a	substantial	public	
health	impact.	It	also	suggests	repeat	vaccination	may	have	utility	in	temperate	climates	in	seasons	
when	the	virus	circulates	for	longer	than	is	typical.		
Further	study	with	different	populations,	vaccines,	vaccine	strains	and	over	more	seasons	are	
required	to	confirm	that	these	study	findings	are	reproducible,	and	a	number	of	points	warrant	
further	consideration.	
The	major	concern	with	a	six-monthly	vaccination	schedule,	is	whether	repeat	vaccination	might	
result	in	lower	vaccine	effectiveness	compared	with	an	annual	schedule.	Reduced	vaccine	
effectiveness	with	sequential	years	vaccination	has	been	reported	from	a	number	of	test-negative	
design	case-control	studies.	We	observed	a	significantly	reduced	antibody	response	at	the	second	
influenza	vaccination,	suggesting	interference	from	pre-vaccination	immunity.	While	the	motivation	
for	six-monthly	vaccination	is	to	overcome	the	problem	with	waning	of	immunity	in	older	adults,	this	
study	finds	data	to	support	the	notion	that	waning	is	itself	important	to	stimulate	a	rise	in	HI	titre.		
The	reduced	HI	response	between	first	and	second	vaccination	across	a	range	of	baseline	titres	
implies,	however,	that	it	is	not	simply	the	quantity	of	pre-vaccination	antibody	which	predicts	
vaccine	response.	Instead,	qualitative	differences	in	the	post-vaccination	antibodies	may	be	more	
important.	In	the	TROPICS1	cohort,	prior	vaccination	was	uncommon	(11%	in	the	past	two	years).	
Pre-vaccination	antibody	hence	largely	reflects	previous	infection.	Compared	with	infection,	the	
breadth	of	the	antibody	repertoire	following	vaccination	is	reduced,	and	appears	to	be	more	focused	
towards	epitopes	of	the	HA	head	which	are	variable	between	strains.20	Repeat	vaccination	with	the	
same	influenza	strains	may	result	in	rapid	neutralisation	from	circulating	antibody,	but	poorly	boost	
memory	responses	in	a	phenomenon	known	as	antigen	trapping.21	Possible	solutions	to	this	problem	
include	vaccinating	with	strains	that	have	drifted	sufficiently	from	the	previous	vaccinating	strain,	
and	so	are	neutralised	less	effectively	by	circulating	antibody.22	Alternatively,	in	the	absence	of	
vaccine	strain	change,	memory	responses	may	be	more	effectively	stimulated	with	adjuvants	or	a	
higher	antigen	dose.		
As	even	at	low	or	undetectable	pre-vaccination	titres	the	HI	response	to	repeat	vaccination	was	also	
reduced	compared	with	first	vaccination,	other	components	of	the	immune	response	are	also	likely	
to	be	important.	For	example,	neuraminidase	(NA)	inhibiting	antibodies	are	stimulated	by	
vaccination	and	provide	an	independent	measure	of	protection	against	infection.23	The	time-course	
of	these	and	other	vaccine-induced	antibodies	in	the	months	after	vaccination	is	not	known.	While	
cell-mediated	immunity	is	typically	poorly	stimulated	by	the	inactivated	influenza	vaccine,	repeat	
vaccination	has	been	associated	with	diminished	T-cell	responses.13	
Despite	this	interference,	there	was	clear	evidence	of	an	immune	response	to	repeat	influenza	
vaccination	and	reduced	waning	of	titres	by	Month	12	compared	with	the	control	group	–	most	
clearly	described	by	the	difference	in	GMFR	between	the	two	vaccination	groups.	This	immune	
response	may	explain	the	unexpected	finding	of	a	significant	reduction	in	the	incidence	of	influenza-
like-illness	(ILI)	and	healthcare	utilisation.	The	observed	ILI	attack	rate	of	12%,	is	similar	to	
conventional	estimates	of	a	5-15%	annual	influenza	infection	rate,	but	is	a	non-specific	endpoint,	
and	other	respiratory	viruses	produce	similar	clinical	symptoms.24	Detecting	a	reduction	in	
virologically	confirmed	influenza	infection	rates,	while	necessary	to	conclude	clinical	benefit,	would	
require	much	larger	sample	sizes.		
A	reduction	in	the	observed	incidence	of	ILI	with	six-monthly	vaccination	may	appear	surprising	
given	the	nominal	‘seroprotection’	rate	(HI≥1:40)	remained	high	in	the	control	group	even	at	Month	
12.	However,	this	threshold	has	been	estimated	to	offer	only	~50%	protection	against	infection,	and		
higher	titres	are	associated	with	a	reduced	risk	of	infection.25	Furthermore,	the	limitations	of	HI	
titres	as	a	catch-all	for	protection	are	well	understood,	and	while	they	are	long	established,	a	better	
correlate	of	protection	is	desirable.	Study	of	other	immune	responses	from	samples	collected	during	
the	TROPICS1	study	are	currently	under	way.		
The	optimal	timing	of	influenza	vaccination	in	Singapore	and	other	tropical	countries	has	not	been	
determined	by	randomised	clinical	trials.	Based	on	epidemiological	studies	of	the	typical	pattern	of	
virus	activity,	Singapore	influenza	vaccination	is	recommended	annually,	and	in	clinical	practice	is	
administered	at	any	time	of	the	year.26	Similar	to	the	difficulties	with	predicting	which	influenza	
strains	to	include	in	vaccines,	variation	in	the	timing	of	influenza	outbreaks	in	tropical	countries	
hampers	prospectively	determining	the	optimal	time	for	vaccination.	The	period	when	the	TROPICS1	
study	was	conducted	–	mainly	the	northern	hemisphere	winter	of	2016/17	and	the	southern	
hemisphere	winter	of	2017	–	recorded	higher	influenza	virus	activity	than	usual.	This	pattern	was	
observed	in	other	countries	in	the	region,	with	a	record	number	of	infections	notified	in	Australia,	
and	an	unusually	prolonged	season	in	Hong	Kong.27,28	Similar	findings	have	also	been	reported	from	
the	Northern	hemisphere	2017/18	winter.29	These	seasons	have	been	dominated	by	A/H3N2	and	
estimates	of	vaccine	effectiveness	against	this	subtype	have	been	low.	As	vaccine	effectiveness	
(particularly	for	A/H3N2)	declines	significantly	3	months	after	vaccination,	some	of	the	apparent	
clinical	benefit	observed	in	this	trial	may	thus	reflect	better	timing	of	vaccination	for	the	epidemic	
peak	in	Singapore,	as	the	majority	of	repeat	influenza	vaccines	were	administered	between	Jan-Apr	
2017.	
The	impact	of	six-monthly	vaccination	also	needs	to	be	considered	in	other	populations	to	the	
TROPICS1	cohort,	which	may	have	different	responses	to	vaccination.	For	example,	similar	to	the	
local	population,	only	10%	of	study	participants	had	received	an	influenza	vaccine	in	the	two	years	
prior	to	study	enrolment,	and	findings	may	be	different	in	a	more	frequently	vaccinated	population.	
Participants	in	this	study	were	also	relatively	well	older	adults.	Adults	at	more	advanced	age,	frailty	
and	with	more	health-limiting	co-morbidities	are	expected	to	have	reduced	immune	responses	
vaccination	and	may	be	more	likely	to	benefit	from	six-monthly	administration.	These	characteristics	
were	probably	not	identified	as	significant	predictors	of	post-vaccination	HI	titres	in	the	TROPICS1	
study	due	to	a	lack	of	statistical	power.		
In	addition	to	the	issues	discussed	above,	data	collection	and	analysis	were	performed	by	study	
personnel	blinded	to	participant	group	allocation,	however,	there	is	a	possibility	of	loss	of	allocation	
concealment	due	to	the	reactogenicity	of	TDaP.	An	active-comparator	was	used	in	the	control	group	
to	avoid	an	‘empty’	injection	in	an	under-vaccinated	population.	In	future	studies	a	saline	injection	
may	be	preferable	to	reduce	this	risk.	The	switch	in	vaccines	manufacturers	between	first	and	
second	influenza	vaccination	may	also	have	interfered	with	vaccine	responses	–	either	positively	or	
negatively	-	but	is	a	pragmatic	consideration	and	would	not	have	impacted	ARI/ILI	incidence.	The	
immune	response	is	thought	to	be	similar	across	inactivated	vaccine	types	(split	or	subunit),	and	this	
switch	reflects	common	practice	in	healthcare	institutions.30		
In	conclusion,	six-monthly	vaccination	in	tropical	and	sub-tropical	countries	offers	promise	as	an	
important	public	health	intervention	for	tropical	and	sub-tropical	to	reduce	the	burden	from	
influenza	infection.	Further	studies	exploring	the	effects	of	repeat	vaccinations	and	strain	changes	
are	important	to	perform	before	concluding	the	immune	and	patient	benefits	of	such	an	approach.			
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